Howard obtained his Bachelor of Business Administration (Law) degree, Bachelor of Laws degree and Postgraduate Certificate in Laws at the University of Hong Kong and was admitted as a solicitor in Hong Kong in 2010.
Prior to joining our firm, Howard has served in various prominent Hong Kong and Chinese law firms which have a major focus on Hong Kong listing and corporate finance practice. He specializes in corporate finance, capital markets and securities transactions including advising issuers and sponsors/underwriters on initial public offerings and listings on the Main Board and GEM of the Hong Kong Stock Exchange, mergers and acquisitions, general corporate and commercial matters as well as regulatory and compliance counseling.
Howard has abundant experience in advising PRC and overseas clients on transactions involving a wide variety of industry sectors such as software development and information technology, entertainment, mining, textile and garment, medical and pharmaceutical, medical equipment, food, bulk cargo terminal, water treatment plant, etc.
Advising TIL Enviro Limited (Stock Code: 1790) on its listing.
Advising Shineroad International Holdings Limited (Stock Code: 1587) on its listing.
Advising Tian Yuan Group Holdings Limited (Stock Code: 6119) on its listing.
Advising Luk Hing Entertainment Group Holdings Limited (Stock Code: 8052) (which was the first listing of a Macau-based clubbing venue operator on the Hong Kong Stock Exchange) on its listing.
Advising Beijing Chunlizhengda Medical Instruments Co., Ltd. on its H-share listing (Stock Code: 1858).
Advising the sponsor and underwriters on the H-share listing of Chanjet Information Technology Company Limited (Stock Code: 1588) (which was the first spin-off listing by an A-share parent company of its subsidiary under a H-share listing on the Hong Kong Stock Exchange).
Advising Magnum Entertainment Group Holdings Limited (Stock Code: 2080) (which was the first Hong Kong nightclub and disco operator listed on the Hong Kong Stock Exchange) on its listing.
Advising Consun Pharmaceutical Group Limited (Stock Code: 1681) on its listing.